Page last updated: 2024-12-11
estradiol-drospirenone combination
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
estradiol-drospirenone combination: consists of 17beta-estradiol and drospirenone; used to treat menopause [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9874151 |
SCHEMBL ID | 8459807 |
MeSH ID | M0491520 |
Synonyms (10)
Synonym |
---|
estradiol-drospirenone combination |
drospirenone and estradiol |
eliq |
350818-73-4 |
bay 86-4891 |
estradiol / drospirenone |
drospirenone / estradiol |
SCHEMBL8459807 |
DTXSID30188582 |
(1r,2r,4r,10r,11s,14s,15s,16s,18s,19s)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol |
Research Excerpts
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" For postmenopausal HRT, 2 mg drospirenone was combined with 1 mg 17beta-estradiol (Angeliq, Schering AG, Berlin, Germany) for continuous treatment." | ( Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Oelkers, WH, 2005) | 0.33 |
"0 mg estradiol in combination with different doses of drospirenone for the treatment of menopausal hot flushes." | ( 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Endrikat, J; Gerlinger, C; Gude, K; Schaefers, M; Schmelter, T, 2015) | 0.42 |
"5 and 1 mg in combination with different drospirenone doses." | ( 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Endrikat, J; Gerlinger, C; Gude, K; Schaefers, M; Schmelter, T, 2015) | 0.42 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 11 (50.00) | 29.6817 |
2010's | 9 (40.91) | 24.3611 |
2020's | 2 (9.09) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 33.29
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.29) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 9 (39.13%) | 5.53% |
Reviews | 8 (34.78%) | 6.00% |
Case Studies | 1 (4.35%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (21.74%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |